When managing an irritated cornea, choosing among fortified antibiotics, oral antivirals, anti-inflammatories or combination ...

Dealing with red, itchy eyelids? The culprit could be a common mite. This article is sponsored by XDEMVY. Dr. Watson is a paid consultant for Tarsus Pharmaceuticals.

Yes, large numbers of Demodex brevis (or Demodex folliculorum) can lead to blepharitis. Demodex mites can live in the folds and along the edges of our eyelids. They remain hidden in the hair ...

Tarsus Pharmaceuticals' Xdemvy (lotilaner) has become the first FDA-approved therapy for Demodex blepharitis, a condition that affects up to 25 million people in the US and can lead to red itchy ...

Lotilaner, approved for Demodex blepharitis, is the only approved treatment, demonstrating high efficacy and strong launch metrics, with $113 million in annual revenue. Despite a Q3 sales dip ...

Treatment for ocular Demodex typically involves an over-the ... Orr: "Eyelash extensions can indeed cause Blepharitis.

This follows a successful 2024 for Tarsus, highlighted by the strong launch of XDEMVY, a treatment for Demodex blepharitis, generating over $113 million in sales. Tarsus is also pursuing ...

IRVINE, Calif., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that management will participate in fireside chats at two upcoming investor conferences: ...

Its product candidate, TP-03, is a novel therapeutic in Phase 2b/3 that is being developed for the treatment of blepharitis caused by the infestation of Demodex mites, which is referred to as ...

Position Trading Today, the company sells one drug that could, potentially, treat 25 million people in the U.S. with Demodex blepharitis, a condition that occurs when mites build up in the eyelashes.

Its product candidate, TP-03, is a novel therapeutic in Phase 2b/3 that is being developed for the treatment of blepharitis caused by the infestation of Demodex mites, which is referred to as ...